

Ming Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10559793/publications.pdf>

Version: 2024-02-01

199
papers

16,184
citations

17440

63
h-index

16650

123
g-index

209
all docs

209
docs citations

209
times ranked

14402
citing authors

#	ARTICLE	IF	CITATIONS
1	Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases. <i>Modern Pathology</i> , 2022, 35, 344-351.	5.5	40
2	Ureter, Urinary Bladder, and Kidney. , 2022, , 487-564.		0
3	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. <i>Nature Medicine</i> , 2022, 28, 154-163.	30.7	143
4	Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. <i>Modern Pathology</i> , 2022, 35, 836-849.	5.5	20
5	<scp>WHO</scp> 2022 landscape of papillary and chromophobe renal cell carcinoma. <i>Histopathology</i> , 2022, 81, 426-438.	2.9	39
6	The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 461-493.	2.5	143
7	Artificial intelligence assistance significantly improves Gleason grading of prostate biopsies by pathologists. <i>Modern Pathology</i> , 2021, 34, 660-671.	5.5	84
8	Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 295.e1-295.e8.	1.6	6
9	Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1167-1184.	5.5	118
10	New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. <i>Modern Pathology</i> , 2021, 34, 1392-1424.	5.5	138
11	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. <i>Advances in Anatomic Pathology</i> , 2021, 28, 196-208.	4.3	20
12	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. <i>Advances in Anatomic Pathology</i> , 2021, 28, 179-195.	4.3	23
13	Analytic Sensitivity of 3 Nucleic Acid Detection Assays in Diagnosis of SARS-CoV-2 Infection. <i>journal of applied laboratory medicine</i> , The, 2021, 6, 421-428.	1.3	7
14	Clinical Applications of Immunohistochemistry in Germ Cell Tumors in Men. <i>Methods in Molecular Biology</i> , 2021, 2195, 13-29.	0.9	3
15	Molecular Biomarker Testing in Localized Prostate Cancer: The Critical Role of Pathologists. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 264-265.	2.5	1
16	Prostate Pathology. , 2021, , 133-186.		0
17	Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. <i>American Journal of Cancer Research</i> , 2021, 11, 3990-4001.	1.4	4
18	Juxtaglomerular Cell Tumor With Atypical Pathological Features: Report of a Case and Review of Literature. <i>International Journal of Surgical Pathology</i> , 2020, 28, 87-91.	0.8	11

#	ARTICLE	IF	CITATIONS
19	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology</i> , The, 2020, 21, 222-232.	10.7	364
20	Clinicopathologic features and outcomes of anterior-dominant prostate cancer: implications for diagnosis and treatment. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 435-440.	3.9	11
21	A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients. <i>American Journal of Surgical Pathology</i> , 2020, 44, 98-110.	3.7	69
22	Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens. <i>JAMA Oncology</i> , 2020, 6, 1372.	7.1	119
23	Identification of areas of grading difficulties in prostate cancer and comparison with artificial intelligence assisted grading. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 777-786.	2.8	20
24	Pathology of Renal Cell Carcinoma. , 2020, , 49-72.		2
25	Aberrant integrin α v and α 5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype. <i>Translational Andrology and Urology</i> , 2020, 9, 1630-1638.	1.4	10
26	Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 86-91.	2.5	12
27	Anatomy and Normal Histology of the Prostate Pertinent to Biopsy Interpretation. , 2019, , 1-10.		0
28	Reporting of Prostate Biopsy. , 2019, , 185-194.		0
29	Immunohistochemistry in Prostate Biopsy Evaluation. , 2019, , 33-43.		0
30	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2019, , 45-67.		0
31	Histologic Variants of Acinar Adenocarcinoma, Ductal Adenocarcinoma, Neuroendocrine Tumors, and Other Carcinomas. , 2019, , 69-95.		1
32	Benign Mimics of Prostate Carcinoma. , 2019, , 97-125.		0
33	Intraductal Carcinoma of the Prostate (IDC-P) and Atypical Intraductal Proliferation (AIP). , 2019, , 127-132.		0
34	High-Grade Prostatic Intraepithelial Neoplasia. , 2019, , 133-141.		0
35	Localized Renal Masses: Comment on Recent American Urological Association Guideline. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 659-659.	2.5	3
36	A high-grade renal cell carcinoma with Somatic BRCA2 mutation. <i>Pathology International</i> , 2019, 69, 432-433.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting. <i>Virchows Archiv Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 263-277.	2.8	19
38	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Journal of Clinical Pathology</i> , 2019, 72, 573-578.	2.0	4
39	Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Pathology</i> , 2019, 51, 11-20.	0.6	19
40	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (<scp>ICCR</scp>). <i>Histopathology</i> , 2019, 74, 377-390.	2.9	14
41	Intraoperative Consultation and Macroscopic Handling. <i>American Journal of Surgical Pathology</i> , 2018, 42, e33-e43.	3.7	16
42	Utility of Pathology Imagebase for standardisation of prostate cancer grading. <i>Histopathology</i> , 2018, 73, 8-18.	2.9	36
43	High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. <i>Modern Pathology</i> , 2018, 31, 71-79.	5.5	73
44	The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer. <i>Urology</i> , 2018, 112, 121-125.	1.0	18
45	Multiparametric magnetic resonance imaging identifies significant apical prostate cancers. <i>BJU International</i> , 2018, 121, 239-243.	2.5	13
46	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1571-1584.	3.7	34
47	Challenges in Pathologic Staging of Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1253-1261.	3.7	22
48	Features and Prognostic Significance of Intraductal Carcinoma of the Prostate. <i>European Urology Oncology</i> , 2018, 1, 21-28.	5.4	27
49	Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate. <i>American Journal of Surgical Pathology</i> , 2017, 41, 550-556.	3.7	38
50	Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. <i>Human Pathology</i> , 2017, 63, 149-156.	2.0	89
51	Pathology Imagebase—a reference image database for standardization of pathology. <i>Histopathology</i> , 2017, 71, 677-685.	2.9	19
52	Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC). <i>American Journal of Surgical Pathology</i> , 2017, 41, 1299-1308.	3.7	107
53	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. <i>Urology</i> , 2017, 99, 174-179.	1.0	41
54	Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors. <i>Polish Journal of Pathology</i> , 2017, 68, 284-290.	0.3	5

#	ARTICLE	IF	CITATIONS
55	Molecular Genetic Alterations in Renal Cell Carcinomas With Tubulocystic Pattern: Tubulocystic Renal Cell Carcinoma, Tubulocystic Renal Cell Carcinoma With Heterogenous Component and Familial Leiomyomatosis-associated Renal Cell Carcinoma. Clinicopathologic and Molecular Genetic Analysis of 15 Cases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 521-530.	1.2	11
56	Eosinophilic, Solid, and Cystic Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 60-71.	3.7	139
57	Incidence of intraductal carcinoma, multifocality and bilateral significant disease in radical prostatectomy specimens from Japan and United States. <i>Pathology International</i> , 2016, 66, 672-677.	1.3	5
58	Modification of the pT2 substage classification in prostate adenocarcinoma. <i>Human Pathology</i> , 2016, 56, 57-63.	2.0	12
59	Molecular genetics and immunohistochemistry of renal tumours: translation into clinical practice. <i>Diagnostic Histopathology</i> , 2016, 22, 73-79.	0.4	2
60	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , 2016, 6, 1258-1266.	9.4	66
61	Recent advances in prostate cancer pathology: Gleason grading and beyond. <i>Pathology International</i> , 2016, 66, 260-272.	1.3	28
62	Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. <i>Histopathology</i> , 2016, 69, 441-449.	2.9	82
63	Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. <i>European Urology</i> , 2016, 70, 248-253.	1.9	17
64	New and emerging renal tumour entities. <i>Diagnostic Histopathology</i> , 2016, 22, 47-56.	0.4	3
65	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. <i>European Urology</i> , 2016, 69, 512-517.	1.9	163
66	Solid variant of papillary cystadenoma of the epididymis. <i>Histopathology</i> , 2015, 67, 138-141.	2.9	12
67	Diagnosis of Gleason Pattern 5 Prostate Adenocarcinoma on Core Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1242-1249.	3.7	43
68	Diagnosis of "Poorly Formed Glands" Gleason Pattern 4 Prostatic Adenocarcinoma on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1331-1339.	3.7	67
69	Enhanced IMP3 Expression Activates NF- κ B Pathway and Promotes Renal Cell Carcinoma Progression. <i>PLoS ONE</i> , 2015, 10, e0124338.	2.5	35
70	Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy. <i>American Journal of Surgical Pathology</i> , 2015, 39, 169-178.	3.7	99
71	A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. <i>Lancet Oncology</i> , The, 2015, 16, 676-685.	10.7	229
72	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. <i>Histopathology</i> , 2015, 67, 313-324.	2.9	41

#	ARTICLE	IF	CITATIONS
73	Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 301-305.	1.3	35
74	Disruption of tubular Flcn expression as a mouse model for renal tumor induction. <i>Kidney International</i> , 2015, 88, 1057-1069.	5.2	27
75	Papillary or pseudopapillary tumors of the kidney. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 124-139.	1.5	5
76	Prebiopsy MRI and MRI-ultrasound Fusionâ€‘targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. <i>Urology</i> , 2015, 86, 1192-1199.	1.0	71
77	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. <i>Journal of Urology</i> , 2015, 194, 1601-1606.	0.4	87
78	Mucinous tubular and spindle cell carcinoma of the kidney: Diagnosis by fine needle aspiration and review of the literature. <i>CytoJournal</i> , 2015, 12, 28.	1.7	9
79	Genetic and Epigenetic Alterations in Renal Cell Carcinoma. , 2015, , 407-415.		1
80	The Utility of Immunohistochemistry in the Differential Diagnosis of Renal Cell Carcinomas. , 2015, , 383-399.		1
81	Upper tract urinary cytology to detect upper tract urothelial carcinoma: Using the Johns Hopkins Hospital template and evaluation of its feasibility. <i>CytoJournal</i> , 2015, 12, 17.	1.7	13
82	Differential Expression Patterns of Chicken Ovalbumin Upstream Promoter-Transcription Factor II (COUPTFII) in Primary Renal Cell Neoplasms. <i>American Journal of Clinical Pathology</i> , 2014, 142, A216-A216.	0.7	0
83	Rhabdoid Differentiation Is Associated With Aggressive Behavior in Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1260-1265.	3.7	61
84	Gleason Score 3â€‘+â€‘=7 Prostate Cancer With Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Associated With Low-risk Tumor in Radical Prostatectomy Specimen. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1096-1101.	3.7	78
85	Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors. <i>American Journal of Surgical Pathology</i> , 2014, 38, e35-e49.	3.7	110
86	Re-evaluating the concept of â€‘dominant/index tumor noduleâ€‘in multifocal prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 589-594.	2.8	66
87	Role of microRNA-27a in down-regulation of angiogenic factor ACGF1 under hypoxia associated with high-grade bladder urothelial carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 712-725.	3.8	48
88	Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 57-61.	0.4	52
89	Differential diagnosis of renal tumors with tubulopapillary architecture in children and young adults: a case report and review of literature. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 266-72.	0.4	3
90	Clear cell papillary renal cell carcinoma: a review. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 7312-8.	0.5	24

#	ARTICLE	IF	CITATIONS
91	The impact of location and number of cores on the diagnostic accuracy of renal mass biopsy: an ex vivo study. <i>World Journal of Urology</i> , 2013, 31, 1159-1164.	2.2	23
92	The diagnostic use of ERG in resolving an atypical glands suspicious for cancer diagnosis in prostate biopsies beyond that provided by basal cell and \pm -methylacyl-CoA-racemase markers. <i>Human Pathology</i> , 2013, 44, 786-794.	2.0	42
93	ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma. <i>Human Pathology</i> , 2013, 44, 2241-2246.	2.0	20
94	Pathology of Renal Cell Carcinoma. , 2013, , 23-41.		4
95	Intraductal Carcinoma of Prostate: A Comprehensive and Concise Review. <i>Korean Journal of Pathology</i> , 2013, 47, 307.	1.3	18
96	The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1469-1489.	3.7	922
97	Lymphomas and lymphoproliferative disorders clinically presenting as renal carcinoma: A clinicopathological study of 14 cases. <i>Pathology</i> , 2013, 45, 657-663.	0.6	14
98	Intraductal carcinoma of the prostate: the whole story. <i>Pathology</i> , 2013, 45, 533-539.	0.6	26
99	Bilateral Tubulocystic Renal Cell Carcinomas in Diabetic End-Stage Renal Disease: First Case Report with Cytogenetic and Ultrastructural Studies. <i>Rare Tumors</i> , 2013, 5, 185-188.	0.6	2
100	Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. <i>Histopathology</i> , 2013, 63, 574-579.	2.9	80
101	Metanephric adenoma and solid variant of papillary renal cell carcinoma: common and distinctive features. <i>Histopathology</i> , 2013, 62, 941-953.	2.9	54
102	Localized Cystic Disease of the Kidney. <i>American Journal of Surgical Pathology</i> , 2013, 37, 506-513.	3.7	22
103	Pathology of Renal Cell Carcinoma. , 2013, , 51-69.		1
104	Atypical Cribriform Lesions of the Prostate. <i>Advances in Anatomic Pathology</i> , 2012, 19, 270-278.	4.3	44
105	Carcinoma of the Collecting Ducts of Bellini and Renal Medullary Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1265-1278.	3.7	127
106	ERG Protein Expression in Human Tumors Detected With a Rabbit Monoclonal Antibody. <i>American Journal of Clinical Pathology</i> , 2012, 138, 803-810.	0.7	53
107	BRAF Mutations in Metanephric Adenoma of the Kidney. <i>European Urology</i> , 2012, 62, 917-922.	1.9	95
108	Do Not Misinterpret Intraductal Carcinoma of the Prostate as High-grade Prostatic Intraepithelial Neoplasia!. <i>European Urology</i> , 2012, 62, 518-522.	1.9	26

#	ARTICLE	IF	CITATIONS
109	Intraductal Carcinoma of the Prostate. Archives of Pathology and Laboratory Medicine, 2012, 136, 418-425.	2.5	55
110	Expression of ERG protein, a prostate cancer specific marker, in high grade prostatic intraepithelial neoplasia (HGPIN): lack of utility to stratify cancer risks associated with HGPIN. BJU International, 2012, 110, E751-5.	2.5	19
111	Pathology of Genitourinary Malignancies: Implications for Clinical Management. Seminars in Oncology Nursing, 2012, 28, 143-153.	1.5	1
112	Immunohistochemistry in Prostate Biopsy Evaluation. , 2012, , 29-40.		0
113	Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: Implications for focal therapy. Prostate, 2012, 72, 1179-1186.	2.3	34
114	Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study.. Journal of Clinical Oncology, 2012, 30, 139-139.	1.6	1
115	Benign Mimics of Prostate Carcinoma. , 2012, , 79-113.		0
116	High-Grade Prostatic Intraepithelial Neoplasia. , 2012, , 121-130.		0
117	Atypical Cribriform Lesions of the Prostate Gland: Emerging Concepts of Intraductal Carcinoma of the Prostate (IDC-P). , 2012, , 115-120.		0
118	Reporting of Prostate Biopsy. , 2012, , 173-180.		0
119	Contemporary Approach to Gleason Grading of Prostate Cancer. , 2012, , 41-55.		0
120	Molecular Biology of Prostate Cancer and Emerging Diagnostic and Prognostic Biomarkers. , 2012, , 157-167.		0
121	Histologic Variants of Prostate Carcinoma. , 2012, , 57-78.		0
122	Single Focus Prostate Cancer: Pathological Features and ERG Fusion Status. Journal of Urology, 2011, 185, 489-494.	0.4	15
123	Benign mimickers and potential precursors of prostatic adenocarcinoma. Diagnostic Histopathology, 2011, 17, 434-446.	0.4	0
124	Mixed Epithelial and Stromal Tumors of the Kidney. American Journal of Surgical Pathology, 2011, 35, 1114-1122.	3.7	31
125	The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With "Atypical Glands Suspicious for Cancer" American Journal of Surgical Pathology, 2011, 35, 608-614.	3.7	59
126	The Utility of ERG/P63 Double Immunohistochemical Staining in the Diagnosis of Limited Cancer in Prostate Needle Biopsies. American Journal of Surgical Pathology, 2011, 35, 1062-1068.	3.7	67

#	ARTICLE	IF	CITATIONS
127	Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence. American Journal of Surgical Pathology, 2011, 35, 1134-1139.	3.7	93
128	Renal mass sampling: An enlightened perspective. International Journal of Urology, 2011, 18, 5-19.	1.0	47
129	ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 441-447.	2.8	77
130	ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients. Prostate, 2011, 71, 489-497.	2.3	239
131	Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase II α inhibiting therapy. BJU International, 2010, 106, 62-65.	2.5	46
132	Atypical Cribriform Lesions of the Prostate: Relationship to Prostatic Carcinoma and Implication for Diagnosis in Prostate Biopsies. American Journal of Surgical Pathology, 2010, 34, 470-477.	3.7	80
133	Primary Leiomyosarcoma of the Kidney: A Clinicopathologic Study of 27 Cases. American Journal of Surgical Pathology, 2010, 34, 238-242.	3.7	53
134	Distinguishing Clear Cell Renal Cell Carcinoma, Retroperitoneal Paraganglioma, and Adrenal Cortical Lesions on Limited Biopsy Material. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 414-421.	1.2	21
135	Ovarian-type Stroma in Cystic Nephroma. American Journal of Surgical Pathology, 2010, 34, 127.	3.7	0
136	ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate. American Journal of Surgical Pathology, 2010, 34, 478-485.	3.7	91
137	Clear Cell Tubulopapillary Renal Cell Carcinoma: A Study of 36 Distinctive Low-grade Epithelial Tumors of the Kidney. American Journal of Surgical Pathology, 2010, 34, 1608-1621.	3.7	185
138	ERG rearrangement is present in a subset of transition zone prostatic tumors. Modern Pathology, 2010, 23, 1499-1506.	5.5	52
139	Renal Epithelioid Angiomyolipoma With Atypia: A Series of 40 Cases With Emphasis on Clinicopathologic Prognostic Indicators of Malignancy. American Journal of Surgical Pathology, 2010, 34, 715-722.	3.7	203
140	Clinicopathological features of prostate cancers detected after an initial diagnosis of "atypical glands suspicious for cancer". Pathology, 2010, 42, 334-338.	0.6	11
141	Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma. Cancer Research, 2010, 70, 1063-1071.	0.9	394
142	Quantification of Carbonic Anhydrase IX Expression in Serum and Tissue of Renal Cell Carcinoma Patients Using Enzyme-linked Immunosorbent Assay: Prognostic and Diagnostic Potentials. Urology, 2010, 75, 257-261.	1.0	60
143	Can Saturation Biopsy Predict Prostate Cancer Localization in Radical Prostatectomy Specimens: A Correlative Study and Implications for Focal Therapy. Urology, 2010, 76, 682-687.	1.0	51
144	Ureter, Urinary Bladder, and Kidney. , 2010, , 487-538.		1

#	ARTICLE	IF	CITATIONS
145	Angiomyolipoma with Minimal Fat on MDCT: Can Counts of Negative-Attenuation Pixels Aid Diagnosis?. American Journal of Roentgenology, 2009, 192, 438-443.	2.2	86
146	Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy. Journal of Clinical Oncology, 2009, 27, 235-241.	1.6	214
147	Gene targeted ablation of high molecular weight fibroblast growth factor-2. Developmental Dynamics, 2009, 238, 351-357.	1.8	25
148	Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor. Modern Pathology, 2009, 22, 385-392.	5.5	29
149	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Modern Pathology, 2009, 22, 1176-1185.	5.5	91
150	Mixed Epithelial and Stromal Tumor of the Kidney. Journal of Urology, 2009, 181, 1879-1880.	0.4	15
151	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney Are the Same Disease Entity. American Journal of Surgical Pathology, 2009, 33, 72-80.	3.7	84
152	Renal Tubulocystic Carcinoma Is Closely Related to Papillary Renal Cell Carcinoma: Implications for Pathologic Classification. American Journal of Surgical Pathology, 2009, 33, 1840-1849.	3.7	121
153	Renal Angiomyolipoma. American Journal of Surgical Pathology, 2009, 33, 289-297.	3.7	216
154	Renal neuroendocrine tumors. Indian Journal of Urology, 2009, 25, 155.	0.6	33
155	Molecular Genitourinary Pathology. , 2009, , 379-392.		2
156	The changing face of renal cell carcinoma pathology. Current Oncology Reports, 2008, 10, 235-244.	4.0	6
157	Prostatic Adenocarcinoma, Prostatic Intraepithelial Neoplasia, and Intraductal Carcinoma. Surgical Pathology Clinics, 2008, 1, 43-75.	1.7	6
158	Adult Cystic Nephroma and Mixed Epithelial and Stromal Tumor of the Kidney: Clinical, Radiographic, and Pathologic Characteristics. Urology, 2008, 71, 1142-1148.	1.0	82
159	von Hippel-Lindau Gene Status and Response to Vascular Endothelial Growth Factor Targeted Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Journal of Urology, 2008, 180, 860-866.	0.4	180
160	Renal Mass Biopsy—A Renaissance?. Journal of Urology, 2008, 179, 20-27.	0.4	344
161	Urothelial Carcinoma and its Variants. Surgical Pathology Clinics, 2008, 1, 159-209.	1.7	7
162	Pathologic Characteristics of Solitary Small Renal Masses. American Journal of Clinical Pathology, 2008, 130, 560-564.	0.7	20

#	ARTICLE	IF	CITATIONS
163	Tubulocystic Carcinoma of the Kidney. American Journal of Surgical Pathology, 2008, 32, 177-187.	3.7	156
164	Pathology of Renal Cell Carcinomas. , 2008, , 55-71.		0
165	Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Neovasculature of Renal Neoplasms. Urology, 2007, 70, 385-390.	1.0	147
166	A Preoperative Prognostic Nomogram for Solid Enhancing Renal Tumors 7 cm or Less Amenable to Partial Nephrectomy. Journal of Urology, 2007, 178, 429-434.	0.4	226
167	Neoadjuvant docetaxel treatment for locally advanced prostate cancer. Cancer, 2007, 110, 1248-1254.	4.1	55
168	The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU International, 2007, 99, 770-774.	2.5	67
169	Renal neuroendocrine tumours: a clinicopathological study. BJU International, 2007, 100, 070907033641008-???.	2.5	64
170	The Prognostic Significance of Epidermal Growth Factor Receptor Expression in Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. Clinical Genitourinary Cancer, 2007, 5, 264-270.	1.9	26
171	Differential Expression of Melanocytic Markers in Myoid, Lipomatous, and Vascular Components of Renal Angiomyolipomas. Archives of Pathology and Laboratory Medicine, 2007, 131, 122-125.	2.5	31
172	Neoplasms of the Prostate and Seminal Vesicles. , 2007, , 56-108.		1
173	Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology, 2006, 68, 825-830.	1.0	64
174	Uncommon Tumors of the Kidney. , 2006, , 1-17.		0
175	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	3.7	123
176	Prostate basal cell lesions can be negative for basal cell keratins: a diagnostic pitfall. , 2006, 28, 125-9.		0
177	The Usefulness of Immunohistochemical Markers in the Differential Diagnosis of Renal Neoplasms. Clinics in Laboratory Medicine, 2005, 25, 247-257.	1.4	138
178	Molecular Genetics of Familial Renal Cell Carcinoma Syndromes. Clinics in Laboratory Medicine, 2005, 25, 259-277.	1.4	68
179	Number and location of nucleoli and presence of apoptotic bodies in diagnostically challenging cases of prostate adenocarcinoma on needle biopsy. Human Pathology, 2005, 36, 1172-1177.	2.0	14
180	Usefulness of Basal Cell Cocktail (34 β E12 + p63) in the Diagnosis of Atypical Prostate Glandular Proliferations. American Journal of Clinical Pathology, 2004, 122, 517-523.	0.7	82

#	ARTICLE	IF	CITATIONS
181	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.9	816
182	QUANTITATIVE GSTP1 METHYLATION LEVELS CORRELATE WITH GLEASON GRADE AND TUMOR VOLUME IN PROSTATE NEEDLE BIOPSIES. <i>Journal of Urology</i> , 2004, 171, 2195-2198.	0.4	48
183	Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. <i>Urology</i> , 2004, 63, 1138-1142.	1.0	140
184	How Often Does Alpha-Methylacyl-CoA-Racemase Contribute to Resolving an Atypical Diagnosis on Prostate Needle Biopsy Beyond That Provided by Basal Cell Markers?. <i>American Journal of Surgical Pathology</i> , 2004, 28, 239-243.	3.7	116
185	Paraganglioma of the Urinary Bladder. <i>American Journal of Surgical Pathology</i> , 2004, 28, 94-100.	3.7	86
186	Cardiac-Specific Overexpression of Fibroblast Growth Factor-2 Protects Against Myocardial Dysfunction and Infarction in a Murine Model of Low-Flow Ischemia. <i>Circulation</i> , 2003, 108, 3140-3148.	1.6	115
187	Basal Cell Cocktail (34 β E12 + p63) Improves the Detection of Prostate Basal Cells. <i>American Journal of Surgical Pathology</i> , 2003, 27, 365-371.	3.7	141
188	Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2003, 27, 772-778.	3.7	128
189	The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers. <i>Pathology</i> , 2003, 35, 472-479.	0.6	15
190	β -Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1662.	7.4	565
191	Comparison of the Basal Cell-Specific Markers, 34 β E12 and p63, in the Diagnosis of Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2002, 26, 1161-1168.	3.7	175
192	Alpha-Methylacyl-CoA Racemase. <i>American Journal of Surgical Pathology</i> , 2002, 26, 926-931.	3.7	274
193	β -Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation. <i>American Journal of Pathology</i> , 2002, 161, 841-848.	3.8	121
194	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002, 419, 624-629.	27.8	2,411
195	Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. <i>Nature Neuroscience</i> , 1999, 2, 246-253.	14.8	332
196	Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. <i>Journal of Clinical Investigation</i> , 1999, 104, 709-719.	8.2	141
197	Fibroblast growth factor 2 control of vascular tone. <i>Nature Medicine</i> , 1998, 4, 201-207.	30.7	348
198	Intracrine and Autocrine Effects of Basic Fibroblast Growth Factor in Vascular Smooth Muscle Cells. <i>Journal of Molecular and Cellular Cardiology</i> , 1997, 29, 1061-1072.	1.9	41

#	ARTICLE	IF	CITATIONS
199	“Papillary Adenoma-like” Renal Tumor with <i>TFE3</i> Gene Rearrangement, A Potential Precursor to or Early Event in the Development of TFE3 Translocation Renal Cell Carcinoma. International Journal of Surgical Pathology, 0, , 106689692211087.	0.8	0